Novartis (NVS) Acquires Majority Stake in Zhejiang Tianyuan Bio-Pharmaceutical for $125 Million

November 9, 2009 2:37 PM EST

Hard To Treat Diseases (OTC: HTDS) announced that Novartis (NYSE: NVS), is acquiring an 85% stake in HTDS' H1N1 Vaccine partner, Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd., for US$125 million.

Novartis of Switzerland will begin a five-year, $1 billion China initiative with two aims: the company will dramatically increase its investment in its China R&D facility, and it will seek to make China one its top three markets worldwide.

HTDS' Chinese subsidiary, Mellow Hope, is the exclusive agent of Zhejiang Tianyuan Bio-pharmaceutical for International marketing and sales. Zhejiang Tianyuan Bio-pharmaceutical has been granted a H1N1 license on September 24, 2009 by the Chinese government agency, SFDA.

[SM]


Related Categories

Corporate News

Stocks Mentioned

HTDS 0.00

+0.00 +100.00%
Volume: 21,306,230
Track HTDS

NVS 53.58

+0.50 +0.94%
Volume: 2,507,700
Track NVS



Comments

mbt shoes
mbt shoes on Nov 10, 2009 06:14 AM

timberland pro boots Womens Roll-Top Boots Womens High Top Boots Womens 6 Inch Boots jack wills Apparel jackwills billy jack wills jack wills mbt trainers mbt shoes mbt shoe mbt sale

ugg for sale
ugg for sale on Nov 10, 2009 06:09 AM

Dunk SB Shoes air max 2009 nike air max 2009 Nike Air Max cardy ugg ugg classic boots UGG Boots UK UGG Boots Sale ugg for sale ugg shoes uggs shoes bailey button uggs


Add Your Comment





Follow StreetInsider.com On Twitter